Ionis will hold second quarter earnings webcast on July 29
Ionis Pharmaceuticals announced that it will hold a webcast at 8:30 a.m. Eastern Time on July 29 to discuss its second quarter 2026 financial results and introduce the progress of key projects. Ionis is a biotechnology company focusing on RNA-targeted therapies, with marketed products and leading R&D pipelines in the fields of neurology, cardiometabolic diseases and other fields. The company currently has six marketed drugs, including TRYNGOLZA (olezarsen), WAINUA (eplontersen), and SPINRAZA (nusinersen) for the treatment of spinal muscular atrophy. This financial report has attracted much attention from the market. In the first quarter of this year, the company's revenue increased 86.4% year-on-year to US$246 million, far exceeding market expectations of US$196 million. GAAP loss per share was US$0.56, which was significantly narrower than the market expected loss of US$0.85. Driven by this, the company raised its full-year revenue guidance for 2026 to US$875 million to US$900 million, and expected its cash reserves to remain above US$1.6 billion at the end of the year. The market generally expects losses to widen in the second quarter, with analysts on average predicting a loss of about $1.06 per share. HC Wainwright previously lowered its second-quarter loss per share forecast to $1.00 from $0.82. Investors will focus on the commercialization progress of the two core products TRYNGOLZA and DAWNZERA, the sustainability of revenue from R&D milestones, and the company's pace of progress toward its 2028 cash flow breakeven goal. Relevant financial report information and live broadcast replays will be provided on the investor relations page of the company's official website.